TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023
September 12, 2023 — Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV,…

TAG Mourns the Loss of Dr. Stephaun Elite Wallace
August 8, 2023 — TAG extends our deepest condolences to the family, friends and loved ones of Dr. Stephaun Elite Wallace, PhD, MS. Dr. Wallace was a treasure to all who knew and worked with him, and his legacy of mentorship and community engagement in the HIV research landscape will be felt for generations.

TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus
August 2, 2023 — Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
July 13, 2023 — After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)…

SMART4TB CONSORTIUM ANNOUNCES COMMUNITY PARTNERS
June 15, 2023 — Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people, that aims to transform tuberculosis (TB) prevention and care.

Treatment Action Group Welcomes Moe Ari Brown as Newest Board Member
June 6, 2023 — Treatment Action Group (TAG) is pleased to announce the election of Moe Ari Brown to our Board of Directors.

The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic
March 28, 2023 — The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.

For World TB Day, TB Advocates Demand Universal Access to Shorter, Safer TB Regimens
March 20, 2023 — On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than they’ve been since the…

TAG Applauds Price Reduction of Molbio’s Truenat Diagnostics for Tuberculosis
March 17, 2023 — Treatment Action Group (TAG) applauds Molbio’s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

CROI 2023 Tuberculosis Research Round Up
February 22, 2023 — Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).